NCT04167761CompletedEarly phase 1

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Source: ClinicalTrials.gov · Last updated 4 Jun 2026

Brief summary (registry, in English)

The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.

Status (registry): Completed
Phase (registry): Early phase 1
Study type: Interventional
Enrollment: 61 (actual)
First submitted: 15 Nov 2019
Start date: 1 Jul 2020
Primary completion date: 31 Dec 2023
Lead sponsor: Stanford University
Diseases: Type 2 diabetes
NCT number: NCT04167761

What you commit to

Study type: Interventional · Early phase 1
Participants enrolled: 61
From 1 Jul 2020 to the primary completion date, 31 Dec 2023
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

currently taking insulin, glp-1 inhibitors, or sulfonylureas

Other illness

allergy or intolerance to interventional medication

Who the study is looking for

patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass surgery or vascular surgery
history of Diabetes Mellitus Type 2 currently diet controlled, or on metformin or dpp4 inhibitors

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Stanford University Coordinator of this site? Confirm its status	Stanford	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.